We are live on ! Find out more
NVO

Novo Nordisk

1,197 hedge funds and large institutions have $23.2B invested in Novo Nordisk in 2023 Q2 according to their latest regulatory filings, with 143 funds opening new positions, 444 increasing their positions, 392 reducing their positions, and 84 closing their positions.

New
Increased
Maintained
Reduced
Closed

70% more first-time investments, than exits

New positions opened: 143 | Existing positions closed: 84

13% more repeat investments, than reductions

Existing positions increased: 444 | Existing positions reduced: 392

5% more capital invested

Capital invested by funds: $22.1B → $23.2B (+$1.11B)

4% more funds holding

Funds holding: 1,1461,197 (+51)

9% more call options, than puts

Call options by funds: $486M | Put options by funds: $448M

0.33% more ownership

Funds ownership: 16.38%16.71% (+0.33%)

16% less funds holding in top 10

Funds holding in top 10: 5647 (-9)

Holders
1,197
Holders Change
+51
Holders Change %
+4.45%
% of All Funds
18.79%
Holding in Top 10
47
Holding in Top 10 Change
-9
Holding in Top 10 Change %
-16.07%
% of All Funds
0.74%
New
143
Increased
444
Reduced
392
Closed
84
Calls
$486M
Puts
$448M
Net Calls
+$38.3M
Net Calls Change
-$29.7M
Name Holding Trade Value Shares
Change
Change in
Stake
CFM
176
Coronation Fund Managers
South Africa
$9.42M +$9.51M +116,416 New
Squarepoint
177
Squarepoint
New York
$9.4M +$7.8M +95,542 +463%
SPIA
178
Steward Partners Investment Advisory
New York
$9.33M -$60.1K -736 -0.6%
CWM
179
Cabot Wealth Management
Massachusetts
$9.29M -$3.18M -38,872 -25%
Cambridge Investment Research Advisors
180
Cambridge Investment Research Advisors
Iowa
$9.21M +$689K +8,436 +8%
SFM
181
Sphera Funds Management
Israel
$9.15M -$2.45M -30,000 -21%
BCAM
182
Boston Common Asset Management
Massachusetts
$9.11M -$2.65M -32,494 -22%
SAM
183
Silvercrest Asset Management
New York
$8.98M -$722K -8,840 -7%
CT
184
Cambridge Trust
Massachusetts
$8.92M
Brown Advisory
185
Brown Advisory
Maryland
$8.91M +$299K +3,660 +3%
GC
186
Grimes & Company
Massachusetts
$8.66M +$40.8K +500 +0.5%
CAM
187
Cresset Asset Management
Illinois
$8.65M +$6.62M +81,000 +312%
LAM
188
Lynch Asset Management
Pennsylvania
$8.64M
BS
189
Banco Santander
Spain
$8.61M -$445K -5,444 -5%
NA
190
Navellier & Associates
Nevada
$8.52M +$3.64M +44,590 +73%
BCWM
191
Bartlett & Co Wealth Management
Ohio
$8.36M
BC
192
Bartlett & Co
Ohio
$8.36M
LNWWM
193
Laird Norton Wetherby Wealth Management
California
$8.28M +$68K +832 +0.8%
SAM
194
Smithbridge Asset Management
Pennsylvania
$8.11M -$227K -2,780 -3%
SGH
195
Sivik Global Healthcare
Connecticut
$8.09M -$1.63M -20,000 -17%
QI
196
QV Investors
Alberta, Canada
$8.04M -$348K -4,260 -4%
HIM
197
Harbour Investment Management
Washington
$8M -$163K -1,992 -2%
RWM
198
Ritholtz Wealth Management
New York
$7.99M +$121K +1,480 +2%
BFS
199
Bard Financial Services
Connecticut
$7.95M -$270K -3,300 -3%
SCP
200
Shorepoint Capital Partners
Massachusetts
$7.6M +$213K +2,606 +3%

NVO Hedge Fund Activity: Q2 2023 in Review

1,197 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Novo Nordisk (NVO) for Q2 2023, worth a combined $23.2B — up 5% from $22.1B a quarter earlier.

Buyers outnumbered sellers: 143 funds opened new NVO positions and 84 closed out — a net gain of 59 holders — while 444 added to existing stakes and 392 trimmed.

The largest buyer was 1832 Asset Management, opening a new position worth an estimated $190M. The largest seller was Envestnet Asset Management, cutting an estimated $578M.

  • 1,197 institutional investors held Novo Nordisk (NVO) as of Q2 2023, up from 1,146 in Q1 2023.
  • Funds reported $23.2B of Novo Nordisk stock for Q2 2023, up 5% quarter-over-quarter.
  • 143 funds opened new Novo Nordisk positions in Q2 2023 and 84 closed out, a net change of +59 holders.
  • The largest Novo Nordisk buyer in Q2 2023 was 1832 Asset Management, an estimated $190M added.
  • The largest Novo Nordisk seller in Q2 2023 was Envestnet Asset Management, an estimated $578M sold.

Based on aggregated 13F filings for Q2 2023.